Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer.
von der Lippe Gythfeldt H, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred Ø, Skjerven H, Schlichting E, Lundgren S, Wist E, Naume B, Kristensen V, Børresen-Dale AL, Lingjaerde OC, Engebraaten O. von der Lippe Gythfeldt H, et al. Among authors: schlichting e. Int J Cancer. 2020 Nov 1;147(9):2515-2525. doi: 10.1002/ijc.33108. Epub 2020 Jun 18. Int J Cancer. 2020. PMID: 32488909 Clinical Trial.
Early detection of breast cancer based on gene-expression patterns in peripheral blood cells.
Sharma P, Sahni NS, Tibshirani R, Skaane P, Urdal P, Berghagen H, Jensen M, Kristiansen L, Moen C, Sharma P, Zaka A, Arnes J, Sauer T, Akslen LA, Schlichting E, Børresen-Dale AL, Lönneborg A. Sharma P, et al. Among authors: schlichting e. Breast Cancer Res. 2005;7(5):R634-44. doi: 10.1186/bcr1203. Epub 2005 Jun 14. Breast Cancer Res. 2005. PMID: 16168108 Free PMC article.
Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.
Russnes HG, Vollan HKM, Lingjærde OC, Krasnitz A, Lundin P, Naume B, Sørlie T, Borgen E, Rye IH, Langerød A, Chin SF, Teschendorff AE, Stephens PJ, Månér S, Schlichting E, Baumbusch LO, Kåresen R, Stratton MP, Wigler M, Caldas C, Zetterberg A, Hicks J, Børresen-Dale AL. Russnes HG, et al. Among authors: schlichting e. Sci Transl Med. 2010 Jun 30;2(38):38ra47. doi: 10.1126/scitranslmed.3000611. Sci Transl Med. 2010. PMID: 20592421 Free PMC article.
DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables.
Kamalakaran S, Varadan V, Giercksky Russnes HE, Levy D, Kendall J, Janevski A, Riggs M, Banerjee N, Synnestvedt M, Schlichting E, Kåresen R, Shama Prasada K, Rotti H, Rao R, Rao L, Eric Tang MH, Satyamoorthy K, Lucito R, Wigler M, Dimitrova N, Naume B, Borresen-Dale AL, Hicks JB. Kamalakaran S, et al. Among authors: schlichting e. Mol Oncol. 2011 Feb;5(1):77-92. doi: 10.1016/j.molonc.2010.11.002. Epub 2010 Dec 2. Mol Oncol. 2011. PMID: 21169070 Free PMC article.
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE. Chrisanthar R, et al. Among authors: schlichting e. PLoS One. 2011 Apr 27;6(4):e19249. doi: 10.1371/journal.pone.0019249. PLoS One. 2011. PMID: 21556366 Free PMC article. Clinical Trial.
171 results